Renewed Focus on Rapid SARS-CoV-2 Testing Has Dx Stakeholders Concerned About Meeting Demand
Premium
After the federal government's investments into rapid and at-home testing, there are concerns whether manufacturers can meet demand.
Castle Biosciences Acquires Cernostics for up to $80M
Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.
The firm measures three proteins and inputs them into an algorithm to determine whether a patient will have a severe reaction to the SARS-CoV-2 virus.
Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions
Premium
The company believes its findings are the first to show that quantifying ctDNA changes can stratify high-risk colorectal cancer patients into better and worse prognostic groups.